Literature DB >> 2353793

A long-term prospective study of optic neuritis: evaluation of risk factors.

M Sandberg-Wollheim1, H Bynke, S Cronqvist, S Holtås, P Platz, L P Ryder.   

Abstract

Eighty-six patients with monosymptomatic optic neuritis of unknown cause were followed prospectively for a median period of 12.9 years. At onset, cerebrospinal fluid (CSF) pleocytosis was present in 46 patients (53%) but oligoclonal immunoglobulin in only 40 (47%) of the patients. The human leukocyte antigen (HLA)-DR2 was present in 45 (52%). Clinically definite multiple sclerosis (MS) was established in 33 patients. Actuarial analysis showed that the cumulative probability of developing MS within 15 years was 45%. Three risk factors were identified: low age and abnormal CSF at onset, and early recurrence of optic neuritis. Female gender, onset in the winter season, and the presence of HLA-DR2 antigen increased the risk for MS, but not significantly. Magnetic resonance imaging detected bilateral discrete white matter lesions, similar to those in MS, in 11 of 25 patients, 7 to 18 years after the isolated attack of optic neuritis. Nine were among the 13 with abnormal CSF and only 2 belonged to the group of 12 with normal CSF (p = 0.01). Normal CSF at the onset of optic neuritis conferred better prognosis but did not preclude the development of MS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2353793     DOI: 10.1002/ana.410270406

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  28 in total

Review 1.  Physicians, subsequence and consequence.

Authors:  W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Lack of restriction of T cell receptor beta variable gene usage in cerebrospinal fluid lymphocytes in acute optic neuritis.

Authors:  R N Heard; S M Teutsch; B H Bennetts; S D Lee; E M Deane; G J Stewart
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-11       Impact factor: 10.154

3.  Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis.

Authors:  M Tintoré; A Rovira; M J Martínez; J Rio; P Díaz-Villoslada; L Brieva; C Borrás; E Grivé; J Capellades; X Montalban
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

4.  Acute Optic Neuritis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-03       Impact factor: 3.598

Review 5.  The ocular manifestations of multiple sclerosis. 1. Abnormalities of the afferent visual system.

Authors:  W I McDonald; D Barnes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-09       Impact factor: 10.154

6.  Immunogenetics of multiple sclerosis and optic neuritis: DNA polymorphism of HLA class II genes.

Authors:  N Morling; M Sandberg-Wollheim; L Fugger; J Georgsen; J J Hylding-Nielsen; H O Madsen; K Rieneck; L Ryder; A Svejgaard
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

7.  Isolated optic neuritis and its prognosis for multiple sclerosis: a clinical and paraclinical study with evoked potentials. CSF examination and brain MRI.

Authors:  A Ghezzi; V Torri; M Zaffaroni
Journal:  Ital J Neurol Sci       Date:  1996-10

8.  [Multiple sclerosis. An update with practical guidelines for ophthalmologists].

Authors:  T Ziemssen; H Wilhelm; F Ziemssen
Journal:  Ophthalmologe       Date:  2006-07       Impact factor: 1.059

9.  Optic neuritis in different strains of mice by a recombinant HSV-1 expressing murine interleukin-2.

Authors:  Mandana Zandian; Raelene Belisle; Kevin R Mott; Steven Nusinowitz; Florence M Hofman; Homayon Ghiasi
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-21       Impact factor: 4.799

10.  Sensitivities and predictive values of paraclinical tests for diagnosing multiple sclerosis.

Authors:  G Filippini; G C Comi; V Cosi; L Bevilacqua; M Ferrarini; V Martinelli; R Bergamaschi; M Filippi; A Citterio; L D'Incerti
Journal:  J Neurol       Date:  1994-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.